Effects of Nicorandil on Systemic Inflammation and Oxidative Stress Induced by Percutaneous Coronary Intervention in Patients with Coronary Heart Disease

Overview

Journal J Int Med Res

Publisher Sage Publications

Specialty General Medicine

Date 2021 Dec 6

PMID 34871513

Citations 2

Authors

Yulong Zong

Jie Li

Xinghua Xu

Xingli Xu

Affiliations

Soon will be listed here.

Abstract

Objective: The present study investigated the effects of a bolus intracoronary injection of nicorandil on systemic inflammation and oxidative stress induced by percutaneous coronary intervention (PCI) in patients with coronary heart disease (CHD).

Methods: Patients undergoing coronary angiography (CAG) were enrolled into the CAG group (n = 30). Patients undergoing PCI were randomly divided into the PCI (n = 30) and PCI + nicorandil groups (n = 30).

Results: Blood taken from patients in the placebo group 24 hours after PCI exhibited significant increases in the expression of inflammatory indicators and mild increases in the expression of anti-inflammatory indicators. The intracoronary injection of nicorandil reversed the elevation of inflammatory indicators and significantly increased the levels of anti-inflammatory indicators in the blood of patients with PCI. Blood taken from patients in the placebo group 24 hours after PCI also displayed significant decreased superoxide dismutase levels and increased malondialdehyde levels. Nicorandil treatment reversed these changes of oxidative stress marker levels.

Conclusions: These results indicated the possible medical application of intracoronary injections of nicorandil for reducing systemic inflammation and oxidative stress in the peripheral blood of patients undergoing PCI.

Citing Articles

Long non-coding RNA SNHG7 serves as a diagnostic biomarker for acute coronary syndrome and its predictive value for the clinical outcome after percutaneous coronary intervention.

Liao R, Han Q, Zhang L J Cardiothorac Surg. 2024; 19(1):450.

PMID: 39014478 PMC: 11251136. DOI: 10.1186/s13019-024-02855-z.

Inflammation and coronary microvascular disease: relationship, mechanism and treatment.

Guo Z, Yang Z, Song Z, Li Z, Xiao Y, Zhang Y Front Cardiovasc Med. 2024; 11:1280734.

PMID: 38836066 PMC: 11148780. DOI: 10.3389/fcvm.2024.1280734.

References

Kim K, Kwak B, Kwon A, Ha J, Kim S, Bae S . Analysis of plasma multiplex cytokines and increased level of IL-10 and IL-1Ra cytokines in febrile seizures. J Neuroinflammation. 2017; 14(1):200. PMC: 5635534. DOI: 10.1186/s12974-017-0974-7. View

Xu X, Liu X, Yu L, Ma J, Yu S, Ni M . Impact of intracoronary nicorandil before stent deployment in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Exp Ther Med. 2019; 19(1):137-146. PMC: 6909796. DOI: 10.3892/etm.2019.8219. View

Testai L, Rapposelli S, Martelli A, Breschi M, Calderone V . Mitochondrial potassium channels as pharmacological target for cardioprotective drugs. Med Res Rev. 2014; 35(3):520-53. DOI: 10.1002/med.21332. View

Pepys M, Baltz M . Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol. 1983; 34:141-212. DOI: 10.1016/s0065-2776(08)60379-x. View

Serizawa K, Yogo K, Aizawa K, Tashiro Y, Takahari Y, Sekine K . Paclitaxel-induced endothelial dysfunction in living rats is prevented by nicorandil via reduction of oxidative stress. J Pharmacol Sci. 2012; 119(4):349-58. DOI: 10.1254/jphs.12067fp. View

Kopetz V, Penno M, Hoffmann P, Wilson D, Beltrame J . Potential mechanisms of the acute coronary syndrome presentation in patients with the coronary slow flow phenomenon - insight from a plasma proteomic approach. Int J Cardiol. 2011; 156(1):84-91. DOI: 10.1016/j.ijcard.2011.09.014. View

Dorge H, Schulz R, Belosjorow S, Post H, van de Sand A, Konietzka I . Coronary microembolization: the role of TNF-alpha in contractile dysfunction. J Mol Cell Cardiol. 2002; 34(1):51-62. DOI: 10.1006/jmcc.2001.1489. View

Matsumoto H, Mikuri M, Masaki R, Tanaka H, Ogura K, Arai T . Feasibility of intracoronary nicorandil for inducing hyperemia on fractional flow reserve measurement: Comparison with intracoronary papaverine. Int J Cardiol. 2020; 314:1-6. DOI: 10.1016/j.ijcard.2020.05.013. View

Soukoulis V, Boden W, Smith Jr S, OGara P . Nonantithrombotic medical options in acute coronary syndromes: old agents and new lines on the horizon. Circ Res. 2014; 114(12):1944-58. PMC: 4083844. DOI: 10.1161/CIRCRESAHA.114.302804. View

10.

Barzyc A, Lysik W, Slyk J, Kuszewski M, Zarebinski M, Wojciechowska M . Reperfusion injury as a target for diminishing infarct size. Med Hypotheses. 2020; 137:109558. DOI: 10.1016/j.mehy.2020.109558. View

11.

Ekelof S, Jensen S, Rosenberg J, Gogenur I . Reduced oxidative stress in STEMI patients treated by primary percutaneous coronary intervention and with antioxidant therapy: a systematic review. Cardiovasc Drugs Ther. 2014; 28(2):173-81. DOI: 10.1007/s10557-014-6511-3. View

12.

Hu K, Wang X, Hu H, Xu Z, Zhang J, An G . Intracoronary application of nicorandil regulates the inflammatory response induced by percutaneous coronary intervention. J Cell Mol Med. 2020; 24(8):4863-4870. PMC: 7176882. DOI: 10.1111/jcmm.15169. View

13.

Wang J, Toan S, Zhou H . New insights into the role of mitochondria in cardiac microvascular ischemia/reperfusion injury. Angiogenesis. 2020; 23(3):299-314. DOI: 10.1007/s10456-020-09720-2. View

14.

Li L, Zhao X, Lu Y, Huang W, Wen W . Altered expression of pro- and anti-inflammatory cytokines is associated with reduced cardiac function in rats following coronary microembolization. Mol Cell Biochem. 2010; 342(1-2):183-90. DOI: 10.1007/s11010-010-0482-x. View

15.

Doll J, Hira R, Kearney K, Kandzari D, Riley R, Marso S . Management of Percutaneous Coronary Intervention Complications: Algorithms From the 2018 and 2019 Seattle Percutaneous Coronary Intervention Complications Conference. Circ Cardiovasc Interv. 2020; 13(6):e008962. DOI: 10.1161/CIRCINTERVENTIONS.120.008962. View

16.

Scholz K, Lengenfelder B, Jacobshagen C, Fleischmann C, Moehlis H, Olbrich H . Long-term effects of a standardized feedback-driven quality improvement program for timely reperfusion therapy in regional STEMI care networks. Eur Heart J Acute Cardiovasc Care. 2020; 10(4):397–405. DOI: 10.1177/2048872620907323. View

17.

Ndrepepa G, Tiroch K, Fusaro M, Keta D, Seyfarth M, Byrne R . 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J Am Coll Cardiol. 2010; 55(21):2383-9. DOI: 10.1016/j.jacc.2009.12.054. View

18.

Su Q, Li L, Liu T, Wang J, Zhou Y, Liu Y . Effects of atorvastatin on PDCD4/NF-κB/TNF-α signaling pathway during coronary microembolization of miniature pigs. Exp Mol Pathol. 2015; 99(3):564-9. DOI: 10.1016/j.yexmp.2015.08.022. View

19.

Yang L, Cong H, Lu Y, Chen X, Liu Y . A nomogram for predicting the risk of no-reflow after primary percutaneous coronary intervention in elderly patients with ST-segment elevation myocardial infarction. Ann Transl Med. 2021; 9(2):126. PMC: 7867879. DOI: 10.21037/atm-20-8003. View

20.

Su Q, Lv X, Sun Y, Yang H, Ye Z, Li L . Role of high mobility group A1/nuclear factor-kappa B signaling in coronary microembolization-induced myocardial injury. Biomed Pharmacother. 2018; 105:1164-1171. DOI: 10.1016/j.biopha.2018.06.098. View